Literature DB >> 11774193

Epstein-Barr viral load measurement as a marker of EBV-related disease.

H Fan1, M L Gulley.   

Abstract

Epstein-Barr virus (EBV) is associated with a wide variety of benign and neoplastic diseases. EBV viral load assays that may prove useful in rapid assessment of disease status are now available. The two most common approaches to viral load measurement are quantitative, competitive PCR, and real-time PCR. Laboratory studies have shown that these assays are sensitive and specific for measuring EBV DNA in blood samples. Clinical investigations suggest a role for viral load measurement in predicting and monitoring EBV-associated tumors, including nasopharyngeal carcinoma, post-transplant lymphoproliferative disorder, Hodgkin's disease, and AIDS-related lymphoma. These new laboratory tools show promise in improving clinical management of affected patients.

Entities:  

Mesh:

Year:  2001        PMID: 11774193     DOI: 10.1054/modi.2001.29161

Source DB:  PubMed          Journal:  Mol Diagn        ISSN: 1084-8592


  15 in total

1.  Epstein-Barr virus-associated pneumonia and bronchiolitis obliterans syndrome in a lung transplant recipient.

Authors:  Andi Krumbholz; Tim Sandhaus; Angela Göhlert; Albert Heim; Roland Zell; Renate Egerer; Martin Breuer; Eberhard Straube; Peter Wutzler; Andreas Sauerbrei
Journal:  Med Microbiol Immunol       Date:  2010-07-20       Impact factor: 3.402

2.  Validation of Roche LightCycler Epstein-Barr virus quantification reagents in a clinical laboratory setting.

Authors:  Margaret L Gulley; Hongxin Fan; Sandra H Elmore
Journal:  J Mol Diagn       Date:  2006-11       Impact factor: 5.568

3.  Epstein-Barr virus-encoded protein kinase (BGLF4) is involved in production of infectious virus.

Authors:  Edward Gershburg; Salvatore Raffa; Maria Rosaria Torrisi; Joseph S Pagano
Journal:  J Virol       Date:  2007-03-14       Impact factor: 5.103

4.  The Epstein-Barr virus (EBV) deubiquitinating enzyme BPLF1 reduces EBV ribonucleotide reductase activity.

Authors:  Christopher B Whitehurst; Shunbin Ning; Gretchen L Bentz; Florent Dufour; Edward Gershburg; Julia Shackelford; Yves Langelier; Joseph S Pagano
Journal:  J Virol       Date:  2009-02-25       Impact factor: 5.103

5.  Comparative evaluation of three commercial quantitative cytomegalovirus standards by use of digital and real-time PCR.

Authors:  R T Hayden; Z Gu; S S Sam; Y Sun; L Tang; S Pounds; A M Caliendo
Journal:  J Clin Microbiol       Date:  2015-02-18       Impact factor: 5.948

6.  Protein kinase inhibitors that inhibit induction of lytic program and replication of Epstein-Barr virus.

Authors:  R Goswami; S Gershburg; A Satorius; E Gershburg
Journal:  Antiviral Res       Date:  2012-10-08       Impact factor: 5.970

7.  Epstein-Barr virus quantitation by real-time PCR targeting multiple gene segments: a novel approach to screen for the virus in paraffin-embedded tissue and plasma.

Authors:  Julie L Ryan; Hongxin Fan; Sally L Glaser; Steven A Schichman; Nancy Raab-Traub; Margaret L Gulley
Journal:  J Mol Diagn       Date:  2004-11       Impact factor: 5.568

8.  Comparison of commercial real-time PCR assays for quantification of Epstein-Barr virus DNA.

Authors:  Guillermo Ruiz; Pilar Peña; Fernando de Ory; Juan Emilio Echevarría
Journal:  J Clin Microbiol       Date:  2005-05       Impact factor: 5.948

9.  Measurement of Epstein-Barr virus DNA load using a novel quantification standard containing two EBV DNA targets and SYBR Green I dye.

Authors:  Meav-Lang J Lay; Robyn M Lucas; Mala Ratnamohan; Janette Taylor; Anne-Louise Ponsonby; Dominic E Dwyer
Journal:  Virol J       Date:  2010-09-22       Impact factor: 4.099

10.  SPLUNC1 regulates cell progression and apoptosis through the miR-141-PTEN/p27 pathway, but is hindered by LMP1.

Authors:  Pan Chen; Xiaofang Guo; Houde Zhou; Wenling Zhang; Zhaoyang Zeng; Qianjin Liao; Xiayu Li; Bo Xiang; Jianbo Yang; Jian Ma; Ming Zhou; Shuping Peng; Juanjuan Xiang; Xiaoling Li; Colvin Wanshura L E; Wei Xiong; James B McCarthy; Guiyuan Li
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.